ISIC Q86 · United States · 5 publishers
Healthcare in United States
444 verified figures for United States, covering 45 indicators from 5 primary sources. Every figure links to the report it came from.
United States compared
| Measure | United States | World | Highest country |
|---|---|---|---|
| Current health expenditure (CHE) as percentage of GDP (%) | 16.7%United States · 2023 | — | 27.1%Tuvalu · 2023 |
| Domestic general government health expenditure as percentage of GDP (%) | 9.01%United States · 2023 | — | 19.7%Tuvalu · 2023 |
| Oncology novel active substance (NAS) launches (cumulative) | 85United States · 2020–2024 | 132World · 2020–2024 | United States is highest |
| Novel active substance launches | 53United States · 2025 | 79World · 2025 | United States is highest |
| Novel active substance launches, five-year total | 270United States · 2021–2025 | 388World · 2021–2025 | United States is highest |
The short version
Key takeaways
Market size and output 4
- Rural Health Transformation Program state investment in the United States was more than 104 million USD (CMS, published 15 September 2026). CMS ↗ T1 Official
- Current health expenditure (CHE) per capita in the United States (US$) was 13,473.2 USD in 2023 (WHO). WHO ↗ T1 Official
- Current health expenditure (CHE) as percentage of GDP in the United States (%) was 16.7% in 2023 (WHO). WHO ↗ T1 Official
- Domestic general government health expenditure as percentage of GDP in the United States (%) was 9.01% in 2023 (WHO). WHO ↗ T1 Official
Growth and change 1
- Net medicine spending growth rate in the United States was 10.6% in 2025 (IQVIA). IQVIA ↗
Adoption and share 1
- DTP3 immunization coverage among 1-year-olds in the United States (%) was 94% in 2025 (WHO). WHO ↗ T1 Official
Other measures 4
- Drug overdose deaths in the United States were 67,798 in 2025–2026 (CDC). CDC ↗ T1 Official
- Lung cancer screening rate among eligible program members in the United States was 54% in 2024 (CDC). CDC ↗ T1 Official
- Life expectancy at birth, total in the United States (years) was 78.9 years in 2024 (World Bank). World Bank ↗ T1 Official
- Novel active substance launches in the United States were 53 in 2025 (IQVIA). IQVIA ↗
The complete table
Healthcare data for United States
Every row links to its own page with the full source, verbatim quote and citation.
444 data points across 45 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorPeriodValueSourceType
Adult obesity prevalence (age-standardized, %)+34 more202441%WHOT12024estimate→
Adult obesity prevalence: female (age-standardized, %)+34 more202442.4%WHOT12024estimate→
Adult obesity prevalence: male (age-standardized, %)+34 more202439.6%WHOT12024estimate→
Commercial insurance out-of-pocket cost growth20255%IQVIA2025actual→
Commercial insurance out-of-pocket cost growth (5-year)2020–202537%IQVIA2025actual→
Commercial insurance share of patient out-of-pocket costs202552%IQVIA2025actual→
Current health expenditure (CHE) as percentage of GDP (%)+23 more202316.7%WHOT12023actual→
Current health expenditure (CHE) per capita (US$)+23 more202313,473.2 USDWHOT12023actual→
Domestic general government health expenditure as percentage of GDP (%)+23 more20239.01%WHOT12023actual→
Drug overdose deaths2025–202667,798CDCT12026estimate→
Drug overdose deaths year-over-year change2025–2026-12.3%CDCT12026estimate→
DTP3 immunization coverage among 1-year-olds (%)+25 more202594%WHOT12025estimate→
Five-year cumulative medicine use growth2020–202513%IQVIA2025actual→
Life expectancy at birth, total (years)+64 more202478.9 yearsWorld BankT12024estimate→
Life sciences and patient organization deal value1 Jan 2008 to 5 Oct 20232.4 billion USDIQVIA2023estimate→
Life sciences and patient organization deals1 Jan 2008 to 5 Oct 2023700IQVIA2023estimate→
Lung cancer screening rate among eligible program members202454%CDCT12024actual→
Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%)+25 more202592%WHOT12025estimate→
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%)+25 more202595%WHOT12025estimate→
Medicare out-of-pocket cost decline rate20252.2%IQVIA2025actual→
Medicare out-of-pocket cost increase rate versus 20202020–202523%IQVIA2025actual→
Medicine market average annual growth at net prices (5-year)2021–20259.3%IQVIA2025actual→
NCD mortality rate (per 100,000 population)+21 more2021423.6 per 100,000 peopleWHOT12021estimate→
Net medicine spending growth rate+1 more202510.6%IQVIA2025actual→
Non-retail share of medicine use202516%IQVIA2025actual→
Novel active substance launches+1 more202553IQVIA2025actual→
Novel active substance launches, five-year total2021–2025270IQVIA2025actual→
Oncology novel active substance (NAS) launches (cumulative)2020–202485IQVIA2024actual→
Patient organizations focused on rare diseasesas of 5 Oct 2023593IQVIA2023estimate→
Patient organizations operatingas of 5 Oct 20233,327IQVIA2023actual→
Premature NCD mortality probability (ages 30–70, %)+21 more202113.7%WHOT12021estimate→
Prescription medicine use growth20251.5%IQVIA2025actual→
Prescription medicine use growth (5-year)2021–202513%IQVIA2025actual→
Retail pharmacy prescription drug average annual growth (5-year)2021–20252.4%IQVIA2025actual→
Retail share of medicine use202584%IQVIA2025actual→
Rural Health Transformation Program state investmentas of 15 Sep 2026104 million USDCMST12026actual→
Suicide mortality rate (per 100,000 population)+21 more202114.2 per 100,000 peopleWHOT12021estimate→
Tobacco use prevalence (ages 15+, age-standardized, %)+8 more202415.8%WHOT12024estimate→
Tobacco use prevalence: female (ages 15+, age-standardized, %)+8 more202411.6%WHOT12024estimate→
Tobacco use prevalence: male (ages 15+, age-standardized, %)+8 more202420%WHOT12024estimate→
Showing the 40 best-covered of 45 indicators. Download all 444 rows as CSV
Primary documents
Sources
| Document | Publisher | Authority tier | Accessed | Locator | Data points |
|---|---|---|---|---|---|
| CDC Launches New Overdose Prevention Data Channel Press release | CDC | T1 Official | 16 Sep 2026 | RELEASE | 2 |
| Twenty-Five Years After 9/11 Press release | CDC | T1 Official | 16 Sep 2026 | WTC Health Program lung cancer screening findings | 1 |
| Data Press release | CMS | T1 Official | 16 Sep 2026 | Medicare provider utilization & payment data: Inpatient Hospital Public Use File (PUF) | 2 |
| Newsroom Articles Press release | CMS | T1 Official | 16 Sep 2026 | Trump Administration Announces $104 Million to Transform Rural Healthcare Across Mississippi Through Cutting-Edge Technology and Expanded Care Closer to Home | 1 |
| World Bank life expectancy at birth (total, years) Dataset | World Bank | T1 Official | 3 Oct 2026 | SP.DYN.LE00.IN: {"countryiso3code":"USA","date":"2024","indicator.id":"SP.DYN.LE00.IN"}; SP.DYN.LE00.IN: {"countryiso3code":"USA","date":"2023","indicator.id":"SP.DYN.LE00.IN"}; SP.DYN.LE00.IN: {"countryiso3code":"USA","date":"2022","indicator.id":"SP.DYN.LE00.IN"} | 65 |
| WHO adult obesity prevalence (age-standardized, both sexes) Dataset | WHO | T1 Official | 2 Oct 2026 | NCD_BMI_30A: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; NCD_BMI_30A: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; NCD_BMI_30A: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"} | 35 |
| WHO adult obesity prevalence (age-standardized, female) Dataset | WHO | T1 Official | 2 Oct 2026 | NCD_BMI_30A: {"Dim1":"SEX_FMLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; NCD_BMI_30A: {"Dim1":"SEX_FMLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; NCD_BMI_30A: {"Dim1":"SEX_FMLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"} | 35 |
| WHO adult obesity prevalence (age-standardized, male) Dataset | WHO | T1 Official | 2 Oct 2026 | NCD_BMI_30A: {"Dim1":"SEX_MLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; NCD_BMI_30A: {"Dim1":"SEX_MLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; NCD_BMI_30A: {"Dim1":"SEX_MLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"} | 35 |
| WHO current health expenditure (CHE) as percentage of GDP Dataset | WHO | T1 Official | 2 Oct 2026 | GHED_CHEGDP_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; GHED_CHEGDP_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"}; GHED_CHEGDP_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2021"} | 24 |
| WHO current health expenditure (CHE) per capita in US$ Dataset | WHO | T1 Official | 2 Oct 2026 | GHED_CHE_pc_US_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; GHED_CHE_pc_US_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"}; GHED_CHE_pc_US_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2021"} | 24 |
| WHO/UNICEF DTP3 immunization coverage among 1-year-olds Dataset | WHO | T1 Official | 2 Oct 2026 | WHS4_100: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2025"}; WHS4_100: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; WHS4_100: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"} | 26 |
| WHO domestic general government health expenditure as percentage of GDP Dataset | WHO | T1 Official | 2 Oct 2026 | GHED_GGHE-DGDP_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; GHED_GGHE-DGDP_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"}; GHED_GGHE-DGDP_SHA2011: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2021"} | 24 |
| WHO/UNICEF MCV1 immunization coverage among 1-year-olds Dataset | WHO | T1 Official | 2 Oct 2026 | WHS8_110: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2025"}; WHS8_110: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; WHS8_110: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"} | 26 |
| WHO/UNICEF MCV2 immunization coverage by recommended age Dataset | WHO | T1 Official | 2 Oct 2026 | MCV2: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2025"}; MCV2: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; MCV2: {"SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"} | 26 |
| WHO age-standardized NCD mortality rate (per 100,000 population, both sexes) Dataset | WHO | T1 Official | 3 Oct 2026 | WHS2_131: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2021"}; WHS2_131: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2020"}; WHS2_131: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2019"} | 22 |
| WHO probability of premature death from four main NCDs (ages 30–70, %) Dataset | WHO | T1 Official | 3 Oct 2026 | NCDMORT3070: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2021"}; NCDMORT3070: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2020"}; NCDMORT3070: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2019"} | 22 |
| WHO age-standardized suicide mortality rate (per 100,000 population, both sexes) Dataset | WHO | T1 Official | 3 Oct 2026 | MH_12: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2021"}; MH_12: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2020"}; MH_12: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2019"} | 22 |
| WHO tobacco use prevalence (ages 15+, age-standardized, both sexes) Dataset | WHO | T1 Official | 2 Oct 2026 | M_Est_tob_curr_std: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; M_Est_tob_curr_std: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; M_Est_tob_curr_std: {"Dim1":"SEX_BTSX","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"} | 9 |
| WHO tobacco use prevalence (ages 15+, age-standardized, female) Dataset | WHO | T1 Official | 2 Oct 2026 | M_Est_tob_curr_std: {"Dim1":"SEX_FMLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; M_Est_tob_curr_std: {"Dim1":"SEX_FMLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; M_Est_tob_curr_std: {"Dim1":"SEX_FMLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"} | 9 |
| WHO tobacco use prevalence (ages 15+, age-standardized, male) Dataset | WHO | T1 Official | 2 Oct 2026 | M_Est_tob_curr_std: {"Dim1":"SEX_MLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2024"}; M_Est_tob_curr_std: {"Dim1":"SEX_MLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2023"}; M_Est_tob_curr_std: {"Dim1":"SEX_MLE","SpatialDim":"USA","SpatialDimType":"COUNTRY","TimeDim":"2022"} | 9 |
| Supporting patients through research collaboration Press release | IQVIA | T3 Research | 16 Sep 2026 | Over the past 5 years patient organizations have received over 62.5 billion in revenue; Key findings:; Other findings | 7 |
| U.S. Medicine Use Trends 2026 Press release | IQVIA | T3 Research | 15 Sep 2026 | Other Findings; Key Findings | 14 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 | 1 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 | 2 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | 16 Sep 2026 | Other Findings | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 444 collected records for United States are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Healthcare in United States: statistics. Retrieved from https://statorigin.org/industries/healthcare/united-states